A Fugazi Research report argues ASTC is fundamentally uninvestable with a 99% price correction, citing potential Series D dilution and a lean cash runway. It also raises governance concerns, noting CEO/CTO/Chair roles held by one person and a CFO-related lawsuit. The piece may drive near-term weakness, though material facts require independent verification.
Astrotech unveiled a strategic shift toward Artemis Program opportunities, evaluating lunar-based quantum computing and autonomous platforms. The move comes as the stock breaks to a new 52-week high, with RSI near 93 and price well above key moving averages, suggesting strong momentum but elevated near-term risk if momentum cools.